Kynuramines induce overexpression of heat shock proteins in pancreatic cancer cells Via 5-hydroxytryptamine and MT1/MT2 receptors

Journal of Physiology and Pharmacology

Volumn 66, Issue 5, 2015, Pages 711-718

  Leja Szpak, Anna ^a   Pierzchalski, P ^a   Goralska, M ^a   Nawrot Porabka, K ^a   Bonior, J ^a   Link Lenczowski, P ^a   Jastrzebska, M ^a   Jaworek, J ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

5 hydroxytryptamine receptors; Heat shock protein 27; Heat shock protein 70; Heat shock protein 90 ; L kynurenine; Melatonin receptors; N1 acetyl N2 formyl 5 methoxykynuramine; P heat shock protein 27; Pancreatic carcinoma cells

Indexed keywords

HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; LUZINDOLE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR; SEROTONIN; BEMESETRON; KETANSERIN; KYNURAMINE; MELATONIN; TROPANE DERIVATIVE; TRYPTAMINE DERIVATIVE; TRYPTOPHAN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; HEAT-SHOCK PROTEINS; HUMANS; KETANSERIN; KYNURAMINE; MELATONIN; PANCREATIC NEOPLASMS; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; SEROTONIN; TROPANES; TRYPTAMINES; TRYPTOPHAN;

EID: 84947426115     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Shaib YH, Davila JA, El-Serag HB. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 2006; 24: 87-94.
2. Han SS, Jang JY, Kim SW, et al. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 2006; 32: 271-275.
3. Jaworek J, Leja-Szpak A. Melatonin influences pancreatic cancerogenesis. Histol Histopathol 2014; 29: 423-431.
4. Craig EA, Gambill BD, Nelson RJ. Heat shock proteins: molecular chaperones of protein biogenesis. Microbiol Rev 1993; 57: 402-414.
5. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet 1988; 22: 631-677.
6. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones in tumorigenesis. Trends Biochem Sci 2006; 31: 164-172.
7. Jego G, Hazoume A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett 2013; 332: 275-285.
8. Rogalla T, Ehrnsperger M, Preville X, et al. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem 1999; 274: 18947-18956.
9. Garrido C. Size matters: of the small HSP27 and its large oligomers. Cell Death Differ 2002; 9: 483-485.
10. Bruey JM, Paul C, Fromentin A, et al. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 2000; 19: 4855-4863.
11. Rocchi P, Jugpal P, So A, et al. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int 2006; 98: 1082-1089.
12. Nakashima M, Adachi S, Yasuda I, et al. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells. Cancer Lett 2011; 313: 218-225.
13. Li C, Lee JS, Ko YG, Kim JI, Seo JS. Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation. J Biol Chem 2000; 275: 25665-25671.
14. Pierzchalski P, Jastrzebska M, Link-Lenczowski P, et al. The dynamics of heat shock system activation in Monomac-6 cells upon Helicobacter pylori infection. J Physiol Pharmacol 2014; 65: 791-800.
15. Stankiewicz AR, Lachapelle G, Foo CP, Radicioni SM, Mosser DD. Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax translocation. J Biol Chem 2005; 280: 38729-38739.
16. Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000; 2: 469-475.
17. Komarova EY, Afanasyeva EA, Bulatova MM, Cheetham ME, Margulis BA, Guzhova IV. Downstream caspases are novel targets for the antiapoptotic activity of the molecular chaperone hsp70. Cell Stress Chaperones 2004; 9: 265-275.
18. Santarosa M, Favaro D, Quaia M, Galligioni E. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer 1997; 33: 873-877.
19. Song L, Xu Z, Zhang C, Qiao X, Huang C. Up-regulation of the HSP72 by Foxa1 in MCF-7 human breast cancer cell line. Biochem Biophys Res Commun 2009; 386: 30-34.
20. Aghdassi A, Phillips P, Dudeja V, et al. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res 2007; 67: 616-625.
21. Dudeja V, Mujumdar N, Phillips P, et al. Heat shock protein 70 inhibits apoptosis in cancer cells through simultaneous and independent mechanisms. Gastroenterology 2009; 136: 1772-1782.
22. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-772.
23. Pandey P, Saleh A, Nakazawa A, et al. Negative of regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 2000; 19: 4310-4322.
24. Hsu P, Hsu SM. Abundance of heat shock proteins (hsp89, hsp60 and hsp27) in malignant cells of Hodgin’s disease. Cancer Res 1998; 58: 5507-5513.
25. Tsutsumi S, Scroggins B, Koga F, et al. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2008; 27: 2478-2487.
26. Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC. Heat shock protein 90: inhibitors in clinical trials. J Med Chem 2010; 53: 3-17.
27. Ogata M, Naito Z, Tanaka S, Moriyama Y, Asano G. Overexpression and localization of heat shock protein mRNA in pancreatic carcinoma. J Nippon Med Sch 2000; 67: 177-185.
28. Jaworek J, Leja-Szpak A, Bonior J, et al. Protective effect of melatonin and its precursor L-tryptophan on acute pancreatitis induced by caerulein overstimulation or ischemia/reperfusion. J Pineal Res 2003; 34: 40-52.
29. Jaworek J, Nawrot-Porabka K, Leja-Szpak, et al. Melatonin as modulator of pancreatic enzyme secretion and pancreatoprotector. J Physiol Pharmacol 2007; 58(Suppl. 6): 65-80.
30. Bonior J, Jaworek J, Konturek SJ, Pawlik WW. Increase of heat shock protein gene expression by melatonin in AR42J cells. J Physiol Pharmacol 2005; 56: 471-481.
31. Jaworek J, Szklarczyk J, Jaworek AK, Nawrot-Porabka K, Leja-Szpak A, Bonior J, Kot M. Protective effect of melatonin on acute pancreatitis. Int J Inflamm 2012; 2012: 173675.
32. Leja-Szpak A, Jaworek J, Szklarczyk J, Konturek SJ, Pawlik WW. Melatonin stimulates HSP27 phosphorylation in human pancreatic carcinoma cells (PANC-1). J Physiol Pharmacol 2007; 58(Suppl. 3): 177-188.
33. Leja-Szpak A, Jaworek J, Pierzchalski P, Reiter RJ. Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 2010; 49: 248-255.
34. Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47: 109-126.
35. Rozov SV, Filatova EV, Orlov AA, et al. N1-acetyl-N2-formyl-5-methoxykynuramine is a product of melatonin oxidation in rats. J Pineal Res 2003; 35: 245-250.
36. Onuki J, Almeida EA, Medeiros MH, Di Mascio P. Inhibition of 5-aminolevulinic acid-induced DNA damage by melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, quercetin or resveratrol. J Pineal Res 2005; 38: 107-115.
37. Manda K, Ueno M, Anzai K. AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res 2007; 42: 386-393.
38. Niu S, Li F, Tan DX, et al. Analysis of N1-acetyl-N2-formyl-5-methoxykynuramine/N1-acetyl-5-methoxy-kynuramine formation from melatonin in mice. J Pineal Res 2010; 49: 106-114.
39. Ma X, Idle JR, Krausz KW, Tan DX, Ceraulo L, Gonzalez FJ. Urinary metabolites and antioxidant products of exogenous melatonin in the mouse. J Pineal Res 2006; 40: 343-349.
40. Sucher R, Kurz K, Weiss G, Margreiter R, Fuchs D, Brandacher G. IDO-mediated tryptophan degradation in the pathogenesis of malignant tumor disease. Int J Tryptophan Res 2010; 3: 113-120.
41. Lob S, Konigsrainer A, Zieker D, et al. IDO1 and IDO2 are expressed in human tumors: levo-but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009; 58: 153-157.
42. King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 2007; 39: 2167-2172.
43. Witkiewicz A, Costantino CL, Metz R, et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 2009; 208: 781-787.
44. Witkiewicz A, Williams TK, Cozzitorto J, et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg 2008; 206: 849-854.
45. Koblish HK, Hansbury MJ, Bowman KJ, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 2010; 9: 489-498.
46. Liu X, Shin N, Koblish HK, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010; 115: 3520-3530.
47. Chen C, Jiang X, Lai Y, Liu Y, Zhang Z. Resveratrol protects against arsenic trioxide-induced oxidative damage through maintenance of glutathione homeostasis and inhibition of apoptotic progression. Environ Mol Mutagen 2015; 56: 333-346.
48. Li L, Yue GG, Pu JX, et al. Eriocalyxin B-induced apoptosis in pancreatic adenocarcinoma cells through thiol-containing antioxidant systems and downstream signalling pathways. Curr Mol Med 2014; 14: 673-689.
49. De Jong WH, Smit R, Bakker SJ, de Vries EG, Kema IP. Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 603-609.
50. Paluszkiewicz P, Zgrajka W, Saran T, et al. High concentration of kynurenic acid in bile and pancreatic juice. Amino Acids 2009; 37: 637-641.
51. Kuc D, Zgrajka W, Parada-Turska J, Urbanik-Sypniewska T, Turski WA. Micromolar concentration of kynurenic acid in rat small intestine. Amino Acids 2008; 35: 503-505.
52. Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. J Pineal Res 2013; 54: 245-257.
53. Juszczak M, Roszczyk M, Kowalska E, Stempniak B. The influence of melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamohypophysial system. In vitro and in vivo studies. J Physiol Pharmacol 2014; 65: 777-784.
54. Boutin JA, Marcheteau E, Henning P, et al. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate. J Pineal Res 2008; 45: 524-531.
55. Budu A, Peres R, Bueno VB, Catalani LH, Garcia CR. N1-acetyl-N2-formyl-5-methoxykynuramine modulates the cell cycle of malaria parasites. J Pineal Res 2007; 42: 261-266.
56. Dragicevic N, Copes N, O’Neal-Moffitt G, et al. Melatonin treatment restores mitochondrial function in Alzheimer’s mice: a mitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res 2011; 51: 75-86.
57. Chojnacki C, Walecka-Kapica E, Mokwinska M, et al. Influence of tianeptine on melatonin homeostasis and psychosomatic symptoms in patients with irritable bowel syndrome. J Physiol Pharmacol 2013; 64: 177-183.
58. Koliopanos A, Kleeff J, Xiao Y, et al. Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene 2002; 21: 6059-6070.